Huang Yuelin, Lu Zhenghai, Liu Huanhuan, Yang Ningxin, Chen Yanhong, Wang Chunting, Huang Weixi, Hu Jingjing, Wang Dengbin, Yao Defan
Department of Radiology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
Shanghai University of Sport, Shanghai, 200438, China.
J Nanobiotechnology. 2025 Jun 18;23(1):451. doi: 10.1186/s12951-025-03530-8.
Breast cancer remains the most common malignancy among women worldwide. While traditional computed tomography (CT) scans and image-guided radiotherapy are widely used for breast cancer diagnosis and treatment, their efficacy is often limited.
In this study, we successfully synthesized human serum albumin (HSA)-based KBiF nanoclusters through a simple one-pot biomimetic mineralization strategy. Compared to the clinical contrast agent iohexol, KBiF@HSA significantly enhances dual-energy CT (DECT) imaging contrast at high keV levels, offering improved diagnostic accuracy for breast cancer. Furthermore, KBiF@HSA exhibits a remarkable ability to scavenge elevated glutathione (GSH) levels and promote reactive oxygen species (ROS) generation. When combined with radiotherapy, KBiF@HSA substantially increases X-ray dose deposition at tumor sites, leading to enhanced DNA damage and suppression of breast cancer progression. Importantly, KBiF@HSA demonstrates excellent biocompatibility in vivo, with no significant tissue damage or inflammation observed.
This study presents a novel approach for the development of biocompatible DECT contrast agents and radiosensitizers, offering a promising strategy to enhance breast cancer diagnosis and treatment. However, the efficacy of this approach needs to be further validated across diverse breast cancer subtypes to ensure its broad applicability, which emphasizes the necessity for continued research to fully translate this innovative technology into clinical practice.
乳腺癌仍然是全球女性中最常见的恶性肿瘤。虽然传统的计算机断层扫描（CT）和图像引导放射治疗广泛用于乳腺癌的诊断和治疗，但其疗效往往有限。
在本研究中，我们通过一种简单的一锅法仿生矿化策略成功合成了基于人血清白蛋白（HSA）的KBiF纳米簇。与临床造影剂碘海醇相比，KBiF@HSA在高keV水平下显著增强了双能CT（DECT）成像对比度，提高了乳腺癌的诊断准确性。此外，KBiF@HSA具有显著的清除升高的谷胱甘肽（GSH）水平和促进活性氧（ROS）生成的能力。与放射治疗联合使用时，KBiF@HSA显著增加肿瘤部位的X射线剂量沉积，导致DNA损伤增强并抑制乳腺癌进展。重要的是，KBiF@HSA在体内表现出优异的生物相容性，未观察到明显的组织损伤或炎症。
本研究提出了一种开发生物相容性DECT造影剂和放射增敏剂的新方法，为增强乳腺癌的诊断和治疗提供了一种有前景的策略。然而，这种方法的疗效需要在不同的乳腺癌亚型中进一步验证，以确保其广泛适用性，这强调了持续研究以将这一创新技术完全转化为临床实践的必要性。
